HANOVER, Germany, Dec. 22 /PRNewswire/ -- A recent publication in a biotech journal acknowledges a Top 10 pharmaceutical company has utilized Digilab's sample preparation and fractionation technologies to expose standard and novel diabetes substrates in a Fourier Transform Mass Spectroscopy experimental paradigm (Yates, et al., 2007).
"We evaluated reproducible sample preparation methodologies that could generate pools of candidate substrates for interrogation against any target protease of interest. Fractionation technology from Digilab Biovision GmbH, Hanover, Germany, was adopted for the isolation of low molecular weight peptides (typically <15,000 Da) from human plasma ultrafiltrate." N.A. Yates et al., Int. J. Mass Spectrom. (2006), doi:10.1016/j.ijms.2006.09.020
Digilab's sample preparation procedure offered provided a high enrichment of peptides in biological samples while eliminating high molecular weight protein content, thus enabling a uniquely high sensitivity for peptides in mass spectrometric analyses. Details of the service offer can be found on the website of Digilab "peptidomics.com" http://www.biovision-discovery.de/content/peptide_extraction_services.htm
David Giddings, President and CEO of Digilab, Inc. commented on the publication: "We are pleased our peptidomics sample prep services have proven so beneficial to drug discovery and development work. We look forward to extending these services to other Digilab life sciences industry".
About Digilab
As a global leader in molecular spectroscopy systems for almost 40 years, Digilab develops innovative and differentiated products and services for the life sciences research and in-vitro diagnostics markets. The company's pioneering work for the U.S. Government in 1969 led to the development, manufacture, sales and service of the first commercial Fourier-Transform InfraRed (FTIR) spectrometer. In the fall of 2004, Digilab sold its FTIR molecular spectroscopy assets to Varian Inc. Since then, the company has remained focused on novel and proprietary sample prep, bioinformatics, and spectroscopy detection/analysis devices that can be integrated into solutions for research and diagnostics applications.
In February 2006 Digilab acquired BioVisioN, AG in Hannover, Germany. Digilab is globally commercializing Digilab BioVisioN GmbH's patented Peptidomics(R) products and services and generating IP in this space. Digilab works with companies from the pharmaceutical and diagnostics sectors; analytical instrumentation hardware, software, and consumables suppliers; and academic institutions and government agencies. Digilab has had engagements to discover new biomarkers or drug targets with Astra Zeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Roche Diagnostics, Abbott Laboratories, Johnson and Johnson, and Solvay Pharmaceuticals.
References
Identification of peptidase substrates in human plasma by FTMS based differential mass spectrometry Nathan A. Yates (a), Ekaterina G. Deyanova (a), Wayne Geissler (b), Matthew C. Wiener (c), Jeffrey R. Sachs (c), Kenny K. Wong (b), Nancy A. Thornberry (b), Ranabir Sinha Roy (b), Robert E. Settlage (a), Ronald C. Hendrickson (a)
(a) Department of Molecular Profiling, Proteomics, Merck Research Laboratories, 126 E Lincoln Ave, Rahway NJ 07065, United States
(b) Department of Metabolic Disorders, Merck Research Laboratories, 126 E Lincoln Ave, Rahway NJ 07065, United States
(c) Department of Applied Computer Science and Mathematics, Merck Research Laboratories, 126 E Lincoln Ave, Rahway NJ 07065, United States
Received 16 June 2006; received in revised form 11 September 2006; accepted 12 September 2006
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20061221/CLTH011LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comDigilabCONTACT: Leif Honda, Director of Sales and Marketing of Digilab,+1-781-575-0310, or lhonda@digilabglobal.com
Web site: HTTP://WWW.DIGILABGLOBAL.COM//
